NCT02937571View on ClinicalTrials.gov

High Dose Carfilzomib for Newly Diagnosed Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

October 8, 2024

Study Completion Date

October 8, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Carfilzomib

DRUG

Lenalidomide

DRUG

Dexamethasone

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, East White Plains

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Memorial Sloan Kettering Cancer Center, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Onyx/Amgen

UNKNOWN

collaborator

Celgene

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER